BBIO
BridgeBio Pharma, Inc.Price & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| all-cause mortality risk reduction (acoramidis Phase III open-label extension at month 54) | 45% | Q1 2026 call | — |
| cardiovascular mortality reduction (acoramidis Phase III open-label extension at month 54) | 49% | Q1 2026 call | — |
| genetically confirmed patients in the United States (LGMD2I) | 500 | Q1 2026 call | — |
| mortality risk reduction per mg/dL incremental increase in serum TTR at 30 months | 5% | Q1 2026 call | — |
| NBRx share at JPM talk (Atruvio) | 25% | JPM talk (prior) call | — |
| reduction in diuretic intensification (Atruvio vs tafamidis) | 43% | Q1 2026 call | — |
| share repurchase program authorization | $500M | Q1 2026 call | — |
| time from top-line data to NDA submission (LGMD2I) | 155 | Q1 2026 call | — |
| total new patient starts in the category | 6,100 | Q1 2026 call | — |
| U.S. Atruvio net product revenue growth (quarter over quarter) | 24% | Q1 2026 call | — |
| U.S. Atruvio net product revenue growth (year over year) | 392% | Q1 2026 call | — |
| unaided awareness among prescribing physician community (achondroplasia) | 40% | Q1 2026 call | — |
| unique patient prescriptions | 7,804 | as of February 20, 2026 | — |
| unique prescribers | 1,856 | as of February 20, 2026 | — |
| Prescribers | 1,632 | as of December 31, 2025 | — |
| Unique patient prescriptions written | 6,629 | as of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BBIO
this stock
BridgeBio Pharma, Inc.
|
$15.23B | +1.6% | -88.0% | — | 13.0% |
|
AKTX
Akari Therapeutics Plc
|
$998.08B | -5.7% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.41B | +16.8% | +46.2% | 31.4 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BBIO | +10.7% | +15.5% | +0.7% | +4.4% | +1.7% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | +7.6% | +16.3% | -7.6% | +3.8% | -8.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.